Copyright
©The Author(s) 2021.
World J Gastroenterol. Sep 7, 2021; 27(33): 5520-5535
Published online Sep 7, 2021. doi: 10.3748/wjg.v27.i33.5520
Published online Sep 7, 2021. doi: 10.3748/wjg.v27.i33.5520
Table 2 Summary of treatment in severe acute respiratory syndrome coronavirus-2 negative patients with stable inflammatory bowel disease disease course
Drug | Suggestions | Additional comments |
Continue therapy | ||
Salicylates | Yes | Data from the SECURE-IBD of possible harm need to be confirmed. |
Locally acting steroids | Yes | No specific data available |
Systemic steroids | Yes | Limit use to strictly necessary and taper rapidly |
Azathioprine | Yes | Data from the SECURE-IBD of possible harm need to be confirmed, the risk of reactivation seems to outweigh the risk of continued treatment |
Methotrexate | Yes | Limited data available |
Anti-TNF | Yes | Data from the SECURE-IBD indicate better outcomes compared to other treatments; there are ongoing trials for the treatment of COVID-19 |
Vedolizumab, anti-IL-12/23 | Yes | Limited data available |
Tofacitinib | Yes | Limited data available |
- Citation: Viganò C, Mulinacci G, Palermo A, Barisani D, Pirola L, Fichera M, Invernizzi P, Massironi S. Impact of COVID-19 on inflammatory bowel disease practice and perspectives for the future. World J Gastroenterol 2021; 27(33): 5520-5535
- URL: https://www.wjgnet.com/1007-9327/full/v27/i33/5520.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i33.5520